Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What's Gilead Getting From Kite For Nearly $12bn?

Executive Summary

The $180 per share that Gilead's paying for CAR-T maker Kite was deemed too high by some and just right by others, but the big biotech expects a lot from its new cell therapy platform.

You may also be interested in...



Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal

The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.

Kronos’ Bischofberger Turns To Gilead SYK Inhibitors To Jump Start R&D

Two years after Bischofberger left Gilead for Kronos, he called upon former colleagues to acquire a SYK inhibitor program for a genetically defined subset of acute myelogenous leukemia.

Ready To Make Bigger Biotech Investments, Vida Raises $600m For Second Fund

Scrip spoke with Fred Cohen, who co-founded Vida Ventures with former Kite Pharma CEO Arie Belldegrun, about the venture capital firm's investment focus after raising its second fund in two years.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel